Roth Capital Partners promoted Yasmeen Rahimi, managing director and senior research analyst, to the position of co-head of biotechnology research.
Dr. Rahimi has been a senior research analyst at Roth since 2017, covering companies that are developing therapeutics to treat various liver diseases and conditions, including nonalcoholic steatohepatitis (NASH). She also covers companies that are developing products aligned in the orphan and ultra-orphan therapeutics, as well as women’s health.
Dr. Rahimi trained at Yale University in the laboratory of Dr. Gerald Shulman, a world-renowned endocrinologist who pioneered the understanding of lipid-induced insulin resistance. In addition, she completed her Ph.D. training in the laboratory of Dr. Robert Harris, a distinguished biochemist at Indiana University.
Byron Roth, CEO of Roth, said Dr. Rahimi has demonstrated passion, credibility, and initiative to promote the Roth healthcare practice that is rare for a person with her relatively few years of experience. “She has earned this promotion and we look forward to working with her for years to